The European Commission has cleared U.S. medical equipment-maker Danaher Corp to buy General Electric's healthcare life sciences biopharma business but with divestment conditions.

In February, Danaher said it wanted to buy the GE biopharma business for $21.4 billion – a deal it said would boost the company's presence in the biopharma industry and give it access to tools for research and development of drugs.